Welcome Employees

A password is required to submit a request for an internal transfer. In order to obtain the password you can check any of the following resources: Login to the employee portal, check the current issue of "Regional High Points" newsletter, contact HR, or read this week's "Daily Announcements".

 

Close

Clinical Trials


Clinical trials are research studies on humans with the goal of finding the best way to treat specific diseases. All drugs currently used were once part of a clinical trial at some point in time.

The Hayworth Cancer Center selects trials from several sponsors and a board certified cancer doctor reviews a trial to decide if the trial is safe and reasonable to offer at our facility.

If a decision is made to open a clinical trial, High Point Regional Health System's Institutional Review Board (IRB) reviews the trial for its safety, ethics, and protection of patient's rights. The IRB is made up of volunteers including doctors, nurses, pharmacists, lawyers, chaplains, and members of the community. After the IRB approves the trial, the Hayworth Cancer opens the trial to enrollment.

Participating in a Clinical Trial
  • Ask your doctor if the Hayworth Cancer Center has a trial for your type of cancer or symptom.
  • You doctor will contact a member of the research staff to see if you qualify for a specific trial.
  • Sometimes, one or more of the drugs or tests are paid for by the sponsors of the trial. Otherwise, all standard charges that go along with your treatment are processed the with your private insurance, Medicare or Medicaid.
  • When the research nurse reviews the details of the trial with you, the nurse will tell you if parts of your care will be provided at no cost.
The following clinical trials are in progress for cancer care at our center. If you are interested in participating in a trial, please ask your physician to assess your eligibility.


THE HAYWORTH CANCER CENTER AT HIGH POINT REGIONAL HEALTH CENTER

ONCOLOGY CLINICAL TRIALS CURRENTLY OPEN TO ENROLLMENT



EHO- Emerywood Hematology Oncology
HPRHS- High Point Regional Health System

BLADDER CANCER

CALGB 90601

A study to determine if patients with advanced transitional cell carcinoma treated with bevacizumab, gemzar, and cisplatin is more effective compared to patients treated with gemzar and cisplatin (HPRHS)

BREAST CANCER

DCARE

Stage 2/3 newly diagnosed breast cancer to receive a drug that protects bones and possibly prevents spread of cancer to bones (EHO)

 

 

MA.32

This study, for women with early stage breast cancer, is looking at whether Metformin, an agent commonly used to treat diabetes, can decrease or affect the ability of breast cancer cells to grow and whether Metformin will work with your other breast cancer treatment to keep your cancer from recurring.

 

 

NSABP B-43

A study to determine whether Herceptin given concurrently with radiation therapy is more beneficial in preventing breast cancer recurrence when compared with radiation alone, in those women with HER2-positive (DCIS).ductal carcinoma in situ. (HPRHS)

 

 

SWOG S1007

This study seeks to find out if chemotherapy benefits patients with node-positive breast cancer who have low to intermediate recurrence scores or if hormonal therapy is enough for these patients.

COLON CANCER

MAVERICC TRIAL

Previously un-treated, newly diagnosed pts. with metastatic Colon Cancer treatment of FOLFOX + Avastin vs FOLFIRI + Avastin in a biomarker stratification trial.

 

 

GILEAD 0203

Pts. with metastatic colon cancer that have failed  the 1st chemotherapy regimen of FOLFOX +/- Avastin.  Treatment is FOLFIRI + GS-6624 (new monoclonal antibody)

 

 

SWOG S1013

This is not a treatment study, instead it is a study that is validating a skin assessment tool for oncologists to use in future studies. It requires that you have a diagnosis of either lung or colorectal cancer and that you will receive one of the Epidermal Growth Factor Receptor Inhibitor drugs. These drugs often produce a rash as a side effect. This assessment tool will be used to document the characteristics of the rash.

LUNG CANCER

AMG 782

Stage 3B/4 lung cancer (non small cell) growth factor to help in anemia caused by chemotherapy (EHO)

 

 

ELI LILLY S130

Stage 4 lung cancer (non small cell) previously untreated. This Study compares the standard of care chemo vs. a chemo drug for lung cancer already approved in the previously treated and relapsed setting. (EHO)

 

 

SWOG S0802

This study is for patients with Small Cell Lung Cancer who have previously been treated with a drug called Cisplatin. It offers a second line treatment using Topotecan with or without a study drug called Alfibercept.

 

 

SWOG S1013

This is not a treatment study, instead it is a study that is validating a skin assessment tool for oncologists to use in future studies. It requires that you have a diagnosis of either lung or colorectal cancer and that you will receive one of the Epidermal Growth Factor Receptor Inhibitor drugs. These drugs often produce a rash as a side effect. This assessment tool will be used to document the characteristics of the rash.

LYMPHOMA

 
 

MULTIPLE MYELOMA
AMGEN 482

Patients with newly diagnosed Multiple Myeloma. Treatment is with a drug to treat their bone disease.

MYELODYSPLASTIC SYNDROME
 

NEUROPATHY

 
 

NON HODGKINS LYMPHOMA

GATHER TRIAL

Previously un-treated, newly diagnosed pts. with un-treated advanced diffuse large B-Cell Lymphoma with CHOP chemotherapy + GA101 (Rituxan like monoclonal antibody)

PANCREATIC CANCER
 GILEAD 0101 Patients with newly diagnosed metastatic Adenocarcinoma of the Pancreas, previously untreated.  Treatment is Gemzar + GS-6624 (new monoclonal antibody)

PROSTATE CANCER

CALGB 70807

A study which will test whether a diet-based intervention to increase vegetable and fruit consumption can slow disease progression for men with low-grade prostate cancer on active surveillance.

 

 

CCCWFU 98110

A study to assess the effects of ArginMax on men who are suffering from erectile dysfunction after being treated with radiation for prostate cancer.

 

  

BLADDER VOLUME

A study to evaluate the effects of bladder volume on dose delivery to the rectum in men receiving radiation for prostate cancer. (HPRHS)

For more information, or to determine if you are eligible to participate in any of these trials, contact us by clicking here.  (email to go to oncology_clinical_research@hprhs.com)